Adverse reactions to thalidomide in patients infected with human immunodeficiency virus

Clinical Infectious Diseases

Volumn 24, Issue 6, 1997, Pages 1223-1227

  Haslett, Patrick ^a   Tramontana, Jane ^a   Burroughs, Margaret ^a,b   Hempstead, Margaret ^a   Kaplan, Gilla ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

ADULT; ARTICLE; CONSTIPATION; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; HYPOTENSION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MOOD; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; SEDATION; SKIN MANIFESTATION;

EID: 0030988148     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/513665     Document Type: Article

References (25)

1. Youle M, Clarbour J, Farthing C, et al. Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. BMJ 1989;298:432.
2. Paterson DL, Georghiou PR, Allworth AM, Kemp RJ. Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection. Clin Infect Dis 1995;20:250-4.
3. Klausner JD, Makonkawkeyoon S, Akarasewi P, et al. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11:247-57.
4. Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, et al. Effects of thalidomide on HIV-associated wasting syndrome: a randomized double-blind, placebo-controlled clinical trial. AIDS 1996; 10:1501-7.
5. Berger TG, Huffman C, Thieberg MD. Prurigo nodularis and photosensitivity in AIDS: treatment with thalidomide. J Am Acad Dermatol 1995; 33:837-8.
6. Williams I, Weller IVD, Malin A, Anderson J, Waters MFR. Thalidomide hypersensitivity in AIDS [letter]. Lancet 1991; 337:436-7.
7. Witzenreid FJM. Ūber Schlafst̄rungen. Med Klin 1961;56:1046-9.
8. Waters MFR. An internally-controlled double blind trial of thalidomide in severe erythema nodosum leprosum. Lepr Rev 1971;42:26-42.
9. Van der Yen AJM, Koopmans PP, Vree TB, Van der Meer JWM. Drug intolerance in HIV disease. J Antimicrob Chemother 1994;34:l-5.
10. Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984; 100:663-71.
11. Nunn P, Kibuga D, Gathua S, et al. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet 1991;337:627-30.
12. Pertel P, Hirschtick R. Adverse reactions to dapsone in patients infected with human immunodeficiency virus. Clin Infect Dis 1994; 18:630-2.
13. Kelly JW, Dooley DP, Lattuada CP, Smith CE. A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus. Clin Infect Dis 1992; 14:1034-9.
14. Kletzel M, Beck S, Elser J, Shock N, Burks W. Trimethoprim-sulfamethoxazole oral desensitization in hemophiliacs infected with human immunodeficiency virus with a history of hypersensitivity reactions. Am J Dis Child 1991; 145:1428-9.
15. Nguyen M, Weiss PJ, Wallace MR. Two-day oral desensitization to trimethoprim-sulfamethoxazole in HIV-infected patients. AIDS 1995; 9: 573-5.
16. Para MF, Dohn M, Frame P, et al. ACTG 268 Trial - Gradual initiation of trimethoprim/sulfamethoxazole (T/S) as primary prophylaxis for Pneumocystis carinii pneumonia [abstract no 2]. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections (Washington, DC). Washington, DC: Infectious Diseases Society of America, 1997.
17. McBride WG. Thalidomide and congenital abnormalities [letter]. Lancet 1961;2:1358.
18. Florence AL. Is thalidomide to blame? Br Med J 1960;2:1954.
19. Gardner-Medwin JMM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 1994;53:828-32.
20. Ochinsky S, Verroust J, Basruji-Garin S, Gherardi R, Revuz J. Thalidomide neuropathy incidence and clinicoelectrophysiological findings in 42 patients. Arch Dermatol 1994; 130:66-9.
21. Fuller GN, Jacobs JM, Guiloff RJ. Thalidomide, peripheral neuropathy and AIDS. Int J STD AIDS 1991;2:369-70.
22. Maurer TA, Poncelet A, Badger J, Berger TG. Thalidomide for the treatment of prurigo nodularis of HIV-infected patients [abstract no Tu B2274]. In: Program and abstracts of the 11th International Conference on AIDS (Vancouver). Vancouver: Signals Design Group, 1996.
23. Hawkins DF. Thalidomide for systemic lupus erythematosus [letter]. Lancet 1992:339:1057.
24. Carmichael AJ, Knight A. Thalidomide: a restricted role [letter]. Lancet 1992;339:1362.
25. Corral LG, Muller GW, Moreira AL, et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor a inhibitory activity. Molecular Medicine 1996;2:506-15.